These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 21925231)

  • 21. Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment.
    Nagai T; Kitahara Y; Ibi D; Nabeshima T; Sawa A; Yamada K
    Behav Brain Res; 2011 Nov; 225(1):305-10. PubMed ID: 21835207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
    Mastropaolo J; Rosse RB; Deutsch SI
    Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice.
    Rogóż Z; Wąsik A; Lorenc-Koci E
    Pharmacol Rep; 2018 Aug; 70(4):623-630. PubMed ID: 29885435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GM1 ganglioside reverses the cognitive deficits induced by MK801 in mice.
    Ni YF; Zhang W; Bao XF; Wang W; Song L; Jiang B
    Behav Pharmacol; 2016 Aug; 27(5):451-9. PubMed ID: 26960162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats.
    Boast C; Bartolomeo AC; Morris H; Moyer JA
    Neurobiol Learn Mem; 1999 May; 71(3):259-71. PubMed ID: 10196105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of sensitivity to MK-801 treatment in a novel active allothetic place avoidance task and in the working memory version of the Morris water maze reveals differences between Long-Evans and Wistar rats.
    Vales K; Bubenikova-Valesova V; Klement D; Stuchlik A
    Neurosci Res; 2006 Aug; 55(4):383-8. PubMed ID: 16712995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.
    Reynolds GP; Templeman LA; Zhang ZJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1021-8. PubMed ID: 15953671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NC-1900, an arginine-vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia.
    Matsuoka T; Sumiyoshi T; Tanaka K; Tsunoda M; Uehara T; Itoh H; Kurachi M
    Brain Res; 2005 Aug; 1053(1-2):131-6. PubMed ID: 16051205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alstonine as an antipsychotic: effects on brain amines and metabolic changes.
    Linck VM; Herrmann AP; Piato AL; Detanico BC; Figueiró M; Flório J; Iwu MM; Okunji CO; Leal MB; Elisabetsky E
    Evid Based Complement Alternat Med; 2011; 2011():418597. PubMed ID: 19189988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The action of alstonine.
    WAKIM KG; CHEN KK
    J Pharmacol Exp Ther; 1947 May; 90(1):57-67. PubMed ID: 20241896
    [No Abstract]   [Full Text] [Related]  

  • 34. The alkaloid alstonine: a review of its pharmacological properties.
    Elisabetsky E; Costa-Campos L
    Evid Based Complement Alternat Med; 2006 Mar; 3(1):39-48. PubMed ID: 16550222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of MAP6 deficit, maternal separation and MK801 in female mice: A 3-hit animal model of neurodevelopmental disorder with cognitive deficits.
    Percelay S; Freret T; Turnbull N; Bouet V; Boulouard M
    Behav Brain Res; 2021 Sep; 413():113473. PubMed ID: 34280461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The action of alstonine.
    WAKIM KG; CHEN KK
    Fed Proc; 1947; 6(1):380. PubMed ID: 20249625
    [No Abstract]   [Full Text] [Related]  

  • 37. Further support for a role of the His452Tyr variant in 5-HT2A receptor gene in memory functions in humans.
    Rigbi A; Yakir A; Kanyas K; Pollak Y; Lerer B
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):723-5. PubMed ID: 19292933
    [No Abstract]   [Full Text] [Related]  

  • 38. Enantioselective Syntheses of Yohimbine Alkaloids: Proving Grounds for New Catalytic Transformations.
    Miller ER; Scheidt KA
    Synthesis (Stuttg); 2022; 54(5):1217-1230. PubMed ID: 36187077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Highly Potent Serotonin 5-HT
    Orr MJ; Cao AB; Wang CT; Gaisin A; Csakai A; Friswold AP; Meltzer HY; McCorvy JD; Scheidt KA
    ACS Med Chem Lett; 2022 Apr; 13(4):648-657. PubMed ID: 35450369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplasmodial activity of the natural product compounds alstonine and himbeline.
    Arnold MSJ; Macdonald JR; Quinn RJ; Skinner-Adams TS; Andrews KT; Fisher GM
    Int J Parasitol Drugs Drug Resist; 2021 Aug; 16():17-22. PubMed ID: 33915339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.